PLX - AMEX
Protalix BioTherapeutics, Inc.
$2.01
+1.8%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
At a Glance
Live SnapshotProtalix BioTherapeutics, Inc. Management Team
Mr. Dror Bashan
President, Chief Executive Officer & Director
Compensation
$490,671
Mr. Gilad Mamlok
Senior Vice President & Chief Financial Officer
Mr. Yaron Naos B.Sc., MBA
Senior Vice President of Operations
Compensation
$396,471
Ms. Yael Fellous
Vice President of Human Resources
Protalix BioTherapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $307K and sold $314 worth of PLX shares, resulting in $307K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
56.0K
101.36K
0
0.00
+101K
+$101K
6-9 Months
0
0.00
168
314.00
-314
-$314
9-12 Months
129.0K
205.88K
0
0.00
+206K
+$206K
Top Buyers
Schwartz Aharon
Director
$206K
Bashan Dror
Director, Officer: President And Ceo
$101K
Top Sellers
Bar-Shalev Amos
Director
$314
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $307K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
PLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 25, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 26, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 27, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 18, 2023 | June 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 30, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 30, 2021 | November 24, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | June 04, 2021 | July 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 15, 2020 | June 07, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 15, 2019 | December 09, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 12, 2019 | May 30, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.